文献类型： 外文期刊

作者： Luo, Chaodan ¹ ; Ai, Jingwen ¹ ; Ren, Erfang ¹ ; Li, Jianqiang ¹ ; Feng, Chunmei ¹ ; Li, Xinrong ¹ ; Luo, Xiaojie ¹ ;

作者机构： 1.Guangxi Acad Agr Sci, Guangxi Subtrop Crops Res Inst, Guangxi Inst Subtrop Agr Prod Proc, Subtrop Agr Prod Proc Engn Technol Ctr, 21 Yongwu Rd, Nanning 530001, Guangxi, Peoples R China

关键词： evodiamine; anti-cancer; pharmacokinetic; metabolism; bioavailability

期刊名称：EXPERIMENTAL AND THERAPEUTIC MEDICINE （ 影响因子：2.447； 五年影响因子：2.263 ）

ISSN： 1792-0981

年卷期： 2021 年 22 卷 5 期

页码：

收录情况： SCI

摘要： Evodiae fructus (Wu-Zhu-Yu in Chinese) can be isolated from the dried, unripe fruits of Tetradium ruticarpum and is a well-known traditional Chinese medicine that is applied extensively in China, Japan and Korea. Evodiae fructus has been traditionally used to treat headaches, abdominal pain and menorrhalgia. In addition, it is widely used as a dietary supplement to provide carboxylic acids, essential oils and flavonoids. Evodiamine (EVO) is one of the major bioactive components contained within Evodiae fructus and is considered to be a potential candidate anti-cancer agent. EVO has been reported to exert anti-cancer effects by inhibiting cell proliferation, invasion and metastasis, whilst inducing apoptosis in numerous types of cancer cells. However, EVO is susceptible to metabolism and may inhibit the activities of metabolizing enzymes, such as cytochrome P450. Clinical application of EVO in the treatment of cancers may prove difficult due to poor bioavailability and potential toxicity due to metabolism. Currently, novel drug carriers involving the use of solid dispersion techniques, phospholipids and nanocomplexes to deliver EVO to improve its bioavailability and mitigate side effects have been tested. The present review aims to summarize the reported anti-cancer effects of EVO whilst discussing the pharmacokinetic behaviors, characteristics and effective delivery systems of EVO.